GlassScriptPhysician profile
Lenard Edralin
NPI 1013116599
$1,538.41
in general payments reported to CMS, 2019-2025
17 companies · $152 in 2025
The $152 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $493 · 2020: $206 · 2021: $207 · 2022: $154 · 2023: $114 · 2024: $212 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $477.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $359.15 | 2019-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $259.31 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Pfizer INC. | $201.07 | 2019-2025 | |
| Glaxosmithkline, LLC. | $158.54 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $114.19 | 2024-2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $91.13 | 2020-2021 | |
| Aytu Biopharma, INC. | $67.86 | 2020-2021 | |
| Sanofi Pasteur INC. | $67.29 | 2019-2025 | |
| Corium, LLC | $41.07 | 2022 | |
| Sobi, INC | $37.64 | 2020-2023 | |
| Sanofi-Aventis U.S. LLC | $35.91 | 2025 | |
| Seqirus USA INC | $28.64 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $19.00 | 2019 | |
| Cranial Technologies, INC | $17.24 | 2019 | |
| Novo Nordisk INC | $14.69 | 2025 | Wegovy |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $13.39 | 2022 | |
| Genzyme Corporation | $12.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lenard Edralin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.